Full-Time

Senior Support Manager

Interactive Response Technology, Clinical Supply Chain

Posted on 12/9/2025

Deadline 12/31/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

No salary listed

Hyderabad, Telangana, India

In Person

Site-essential roles require onsite; some roles may be eligible for hybrid with at least 50% onsite.

Category
Operations & Logistics (2)
,
Requirements
  • Minimum bachelor’s degree
  • Minimum of 3 to 5 years work experience preferably in a health science or related IRT industry (pharmaceutical, hospital-based, laboratory, etc.)
  • Demonstrated analytical skills and a working knowledge of Microsoft Office including SharePoint
  • Clinical Research experience
  • Working knowledge of IRT
  • Working knowledge of Clinical Trial Management Systems
  • Working knowledge of clinical supplies
  • Able to think outside of the box, have excellent communication and analytical skills to successfully deliver optimal IRT solutions across a diverse and dynamic portfolio
  • Understand the nature of clinical data and concepts of IRT study design and configuration, resupply settings, blinding, privacy protection, and data quality/integrity standards
  • Exposure to working in a GMP / GCP environment and with regulatory audit teams
  • Possess excellent English language written and verbal communication, interpersonal, collaboration and business partnership capabilities required
  • Comfortable working with a global team, partners and customers in a change agile environment
  • MS Project, MS Visio, or any other requirements visualization and analysis tools
Responsibilities
  • Lead successful maintenance support and projects to ensure execution and on time delivery of Interactive Response Technology (IRT) changes, data and support integrations with other clinical systems (e.g., Depots, Central Lab, and EDC), such that the resultant IRTs are fit-for-purpose as defined by protocol and study operational parameters with special emphasis on adherence to BMS standards and quality principles
  • Works independently and assume support role responsibilities on assigned projects. Collaborate with the IRT Team where necessary to ensure BMS standards and/or for requests by study teams that are not within these standards or best practice are addressed
  • Bring issues of concern or system failure to the immediate attention of the IRT Leadership Team
  • During IRT maintenance act as the primary contact for assigned studies for the cross-functional study team and vendor. Additionally, provide timely response to all randomization/IRT issues (including data integrations and delivery) that arise during IRT lifecycle and ensure they are resolved
  • Maintain vendor performance quality events in ADI log
  • Act as off hours audit/inspection support contact as needed to support rest of world
  • Responsible for generation and oversight of patient and container randomization schedules, ensuring parameters reflect the protocol and drug supply requirements. Distribute patient randomization and container schedules as appropriate to Clinical Supply P&L and IRT vendors
  • Manage special project implementation by identifying project needs, tracking, implementation, and reporting to a central project team
  • Bring issues of concern or system failure to the immediate attention of the IRT Leadership Team
  • Support IRT improvement initiatives and manages improvement projects that impact daily operations to improve efficiency
  • Support key department and enterprise level initiatives as part of the IRT representative
  • Ensure on time delivery of maintenance support and may be involved in user acceptance testing of IRT systems per BMS SOPs and procedures, write or review User Acceptance Test Plan and causes to ensure thorough testing of high –risked areas and new functionality documented in the user requirements
  • Ensure systems and associated documentation are compliant with all Regulatory requirements, including cGMP, 21 CFR Part 11, ICH E6 (R2) as well as in accordance BMS SOPs and processes
  • Ensure effective system access and functionality across all countries and all user locations
  • Complete all assigned training by due date
  • Support unblinding activities as needed
  • Ensure on time development of IRT data transfers with vendors and/or third-party vendors
  • Ensure eTMF compliance at the study level in accordance with group and BMS guidance
  • Engage and support study and CSMT project teams as deemed necessary
  • Ensure delivery of data to BMS departments and third-party vendors consistent with BMS SOPs and forms
  • Additional tasks within scope of expertise and experience as assigned by the supervisor in pursuit of BMS goals
Desired Qualifications
  • None

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE